RxDoctor Payments Data

Robert Eden, MD

Ophthalmology · Slingerlands, NYNPI 1457307811

Payments from drug & device makers

$24,146in general payments, 2019–2025

Across 626 payments — averaging $38.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$9K
  • Alcon$3K
  • Mallinckrodt Hospital Products Inc.$2K
  • AbbVie$2K
  • Bausch & Lomb Americas Inc.$1K
  • Sight Sciences, Inc.$903
  • plus $7K from 26 others

What the payments were for

  • Consulting fees$7,65032%
  • Food & beverage$16,45168%
  • Education$260%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,146 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$353,352
Medicare patients
580
Services billed
3,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj30$932,630
RestasisCyclosporine49$69,043
XiidraLifitegrast29$33,377
Cyclosporine45$22,608
Loteprednol Etabonate85$13,954
Prednisolone Acetate345$11,765
Bromfenac Sodium42$4,285
CombiganBrimonidine Tartrate/Timolol13$3,753
ErythromycinErythromycin Base99$2,971
VigamoxMoxifloxacin Hcl16$2,865
SimbrinzaBrinzolamide/Brimonidine Tart13$2,637
ValacyclovirValacyclovir Hcl36$1,797
Ofloxacin139$1,749
Ketorolac Tromethamine93$1,580
Fluorometholone12$1,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$546$932,63030 claims
AbbVieRestasis, Combigan$1,685$72,79762 claims
Bausch & Lomb Americas Inc.Xiidra$1,230$33,37729 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$347$13,95485 claims
Harrow Eye, LLCVigamox$119$2,86516 claims
AlconSimbrinza$2,813$2,63713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Slingerlands

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →